ArticleJournal of cellular and molecular medicine2026
CTSC Confers Radioresistance in Hepatocellular Carcinoma by Regulating Myeloid-Derived Suppressor Cells.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Radiotherapy is an important therapeutic modality for advanced hepatocellular carcinoma (HCC), but the limited understanding of radioresistance mechanisms in HCC has hindered its further clinical development. This work aimed to clarify the essential role of Cathepsin C (CTSC) in regulating radioresistance in HCC. The expression of CTSC in HCC tissues was analysed using real-time PCR (RT-PCR) and immunohistochemistry. The role of CTSC in radiotherapy resistance of HCC was investigated through in vitro experiments, in vivo studies (subcutaneous and orthotopic liver tumour models) and clinical data analysis. Additionally, in vivo experiments were conducted to evaluate the effect of blocking the CTSC signalling pathway on reversing radiotherapy resistance in HCC. CTSC expression was significantly higher in HCC tissues than in adjacent non-tumour tissues. Correlation analysis showed that positive CTSC expression was positively associated with aggressive clinicopathological features, including increased tumour number, large tumour size, absence of tumour encapsulation, microvascular invasion and advanced TNM stage. Survival analysis further revealed that CTSC overexpression was linked to poorer overall survival (OS) and progression-free survival (PFS) in HCC patients. In vitro experiments demonstrated that CTSC overexpression increased the clonogenic survival rate of Huh7 cells after ionising radiation (IR) and reduced the apoptosis rate. In both subcutaneous and orthotopic liver tumour models, upregulated CTSC expression significantly decreased radiotherapy sensitivity. Clinically, CTSC overexpression was significantly associated with a poor response to radiotherapy. Mechanistically, CTSC promoted the infiltration of myeloid-derived suppressor cells (MDSCs) while reducing CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.